Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Rhythm Pharmaceuticals Announced That The National Institute For Health And Care Excellence Issued Guidance That Recommends Imcivree (setmelanotide) As An Option For Treatment Of Obesity And Hyperphagia In Patients With Bardet-biedl Syndrome

Author: Benzinga Newsdesk | May 22, 2024 04:02am

Posted In: RYTM